Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 4Small Cell Lung Carcinoma 3Advanced Malignant Solid Tumors 3Carcinoma, Non-Small-Cell Lung 2Thymoma 1Stomach Neoplasms 1Renal Cell Cancer Metastatic 1Kidney Neoplasms 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1Advanced Cancer 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × vorolanib × Clear all
NCT03511222 2020-07-29

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

Washington University School of Medicine

Phase 1 Terminated
16 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡